(%)
Market is Open
Last quote from:
After-Hours Quote
Market is closed for
(%)
After-Hours Quote is Unavailable
Market is Open
Last quote from:
After-Hours Quote
Market is closed for
(%)
After-Hours Quote is Unavailable
- Ownership
-
DiaMedica Therapeutics Inc. Executive Compensation
* In original currency USD
Loading Data
|
Filing Date (SEC Report) |
Year | Reporting Name | Salary | Bonus | Stock Award | Incentive Plan Compensation | Other Compensation | Total Amount |
|---|---|---|---|---|---|---|---|---|
| Friday, March 28th, 2025 | 2024 | Scott Kellen Chief Financial Officer and Secretary | 374,250 | 0 | 0 | 147,934 | 17,250 | 813,955 |
| Friday, March 28th, 2025 | 2024 | Lorianne Masuoka, M.D. | 403,277 | 0 | 0 | 116,667 | 17,106 | 1,174,310 |
| Friday, March 28th, 2025 | 2023 | Rick Pauls President and Chief Executive Officer | 562,000 | 0 | 0 | 239,958 | 16,650 | 1,215,161 |
| Friday, March 28th, 2025 | 2024 | Rick Pauls President and Chief Executive Officer | 593,250 | 0 | 0 | 306,975 | 17,250 | 1,550,985 |
| Friday, March 28th, 2025 | 2023 | Scott Kellen Chief Financial Officer and Secretary | 352,750 | 0 | 0 | 116,025 | 16,650 | 632,215 |
| Thursday, April 4th, 2024 | 2023 | Rick Pauls President and Chief Executive Officer | 562,000 | 0 | 0 | 239,958 | 16,650 | 1,215,161 |
| Thursday, April 4th, 2024 | 2022 | Rick Pauls President and Chief Executive Officer | 522,796 | 0 | 0 | 198,342 | 15,650 | 1,080,607 |
| Thursday, April 4th, 2024 | 2023 | Scott Kellen Chief Financial Officer and Secretary | 352,750 | 0 | 0 | 116,025 | 16,650 | 632,215 |
| Thursday, April 4th, 2024 | 2022 | Kirsten Gruis, M.D. Former Chief Medical Officer | 364,167 | 0 | 0 | 137,085 | 15,650 | 1,004,691 |
| Thursday, April 4th, 2024 | 2023 | Kirsten Gruis, M.D. Former Chief Medical Officer | 298,643 | 0 | 0 | 0 | 150,650 | 596,083 |
| Thursday, April 4th, 2024 | 2023 | Julie Daves | 306,754 | 0 | 0 | 91,657 | 16,650 | 533,370 |
| Thursday, April 4th, 2024 | 2022 | Scott Kellen Chief Financial Officer and Secretary | 329,392 | 0 | 0 | 101,983 | 15,650 | 563,574 |
| Tuesday, April 4th, 2023 | 2022 | Kirsten Gruis, M.D. | 364,167 | 0 | 0 | 137,085 | 15,650 | 1,004,691 |
| Tuesday, April 4th, 2023 | 2022 | Scott Kellen Chief Financial Officer and Secretary | 329,392 | 0 | 0 | 101,983 | 15,650 | 563,574 |
| Tuesday, April 4th, 2023 | 2021 | Rick Pauls President and Chief Executive Officer | 477,448 | 0 | 0 | 191,590 | 15,050 | 1,136,169 |
| Tuesday, April 4th, 2023 | 2022 | Rick Pauls President and Chief Executive Officer | 522,796 | 0 | 0 | 198,342 | 15,650 | 1,080,607 |
| Tuesday, April 4th, 2023 | 2021 | Scott Kellen Chief Financial Officer and Secretary | 286,211 | 0 | 0 | 90,460 | 15,050 | 546,720 |
| Tuesday, April 5th, 2022 | 2020 | Rick Pauls President and Chief Executive Officer | 455,013 | 0 | 0 | 217,716 | 14,850 | 878,203 |
| Tuesday, April 5th, 2022 | 2020 | Harry Alcorn, Jr., Pharm.D. Senior Vice President of Clinical Operations | 291,413 | 0 | 0 | 83,662 | 14,850 | 509,065 |
| Tuesday, April 5th, 2022 | 2021 | Harry Alcorn, Jr., Pharm.D. Senior Vice President of Clinical Operations | 302,112 | 0 | 0 | 73,107 | 15,050 | 545,268 |
| Tuesday, April 5th, 2022 | 2021 | Rick Pauls President and Chief Executive Officer | 477,448 | 0 | 0 | 191,590 | 15,050 | 1,136,169 |
| Tuesday, April 5th, 2022 | 2021 | Scott Kellen Chief Financial Officer and Secretary | 286,211 | 0 | 0 | 90,460 | 15,050 | 546,720 |
| Tuesday, April 5th, 2022 | 2020 | Scott Kellen Chief Financial Officer and Secretary | 276,075 | 0 | 0 | 79,238 | 14,850 | 489,303 |
| Thursday, June 3rd, 2021 | 2020 | Harry Alcorn, Jr., Pharm.D. Chief Medical Officer | 291,413 | 0 | 0 | 83,662 | 14,850 | 509,065 |
| Thursday, June 3rd, 2021 | 2020 | Scott Kellen Chief Financial Officer and Secretary | 276,075 | 0 | 0 | 79,238 | 14,850 | 489,303 |
| Thursday, June 3rd, 2021 | 2019 | Rick Pauls President and Chief Executive Officer | 420,000 | 0 | 0 | 178,000 | 14,650 | 733,707 |
| Thursday, June 3rd, 2021 | 2020 | Rick Pauls President and Chief Executive Officer | 455,013 | 0 | 0 | 217,716 | 14,850 | 878,203 |
| Thursday, June 3rd, 2021 | 2019 | Scott Kellen Chief Financial Officer and Secretary | 262,500 | 0 | 0 | 64,800 | 13,950 | 677,807 |
| Thursday, June 3rd, 2021 | 2019 | Harry Alcorn, Jr., Pharm.D. Chief Medical Officer | 273,750 | 0 | 0 | 68,400 | 14,400 | 778,300 |
| Monday, April 20th, 2020 | 2019 | Rick Pauls President and Chief Executive Officer | 420,000 | 0 | 0 | 178,000 | 14,650 | 1,503,386 |
| Monday, April 20th, 2020 | 2019 | Harry Alcorn, Jr., Pharm.D. | 273,750 | 0 | 0 | 68,400 | 14,400 | 778,300 |
| Monday, April 20th, 2020 | 2018 | Scott Kellen Chief Financial Officer and Secretary | 200,833 | 0 | 0 | 70,200 | 9,931 | 642,921 |
| Monday, April 20th, 2020 | 2019 | Scott Kellen Chief Financial Officer and Secretary | 262,500 | 0 | 0 | 64,800 | 13,950 | 677,807 |
| Monday, April 20th, 2020 | 2018 | Rick Pauls President and Chief Executive Officer | 315,208 | 0 | 0 | 163,875 | 13,320 | 733,707 |
| Monday, April 8th, 2019 | 2018 | Todd Verdoorn, Ph.D. Chief Scientific Officer | 221,667 | 0 | 0 | 36,000 | 8,867 | 423,382 |
| Monday, April 8th, 2019 | 2018 | Scott Kellen | 200,833 | 0 | 0 | 70,200 | 9,931 | 642,921 |
| Monday, April 8th, 2019 | 2017 | Rick Pauls President and Chief Executive Officer | 280,000 | 36,667 | 0 | 0 | 17,550 | 501,955 |
| Monday, April 8th, 2019 | 2018 | Rick Pauls President and Chief Executive Officer | 315,208 | 0 | 0 | 163,875 | 13,320 | 733,707 |
| Monday, April 8th, 2019 | 2017 | Todd Verdoorn, Ph.D. Chief Scientific Officer | 200,000 | 40,000 | 0 | 0 | 7,200 | 345,870 |
